Want to see IDYA full AI Analyst Report?
IDYA Stock Chart & Stats
$35.40
-$0.83(-2.29%)
At close: 4:00 PM EDT
$35.40
-$0.83(-2.29%)
Day’s Range― - ―
52-Week Range$22.09 - $40.58
Previous CloseN/A
Volume901.71K
Average Volume (3M)1.20M
Market Cap
$3.50B
Enterprise Value$2.31K
Total Cash (Recent Filing)$671.20M
Total Debt (Recent Filing)$28.60M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Aug 11, 2026EPS Estimate
-1.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding95,083,145
10 Day Avg. Volume777,077
30 Day Avg. Volume1,197,127
Financial Highlights & Ratios
PEG Ratio0.44
Price to Book (P/B)2.99
Price to Sales (P/S)13.99
P/FCF Ratio-41.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$54.11Price Target Upside52.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-4.27
Revenue Forecast (FY)$35.91M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet / Recent Capital RaiseA $323.6M equity raise materially strengthens liquidity and extends runway for R&D-heavy programs. Combined with historically low leverage, this funding reduces near-term financing pressure, enabling multi-year clinical development and strategic collaborations without immediate cash constraints.
High-margin, Improving RevenueMaterial revenue growth and near-100% gross margins indicate collaboration and licensing revenue is highly profitable. Sustained high gross margins center value on partnerships, supporting reinvestment in R&D and showing the business model can scale non-dilutively at the gross-profit level over the medium term.
Robust Strategic Collaborations And Positive Registrational DataPositive Phase 2/3 data and RTOR FDA engagement materially de-risk a lead program's pathway to approval. Alongside collaborations (Roche, AstraZeneca), successful registrational data can unlock milestones, commercialization options, and stronger partner economics, improving long-term commercial prospects.
Bears Say
Persistent Operating Losses And Negative Cash FlowIDEAYA remains loss-making with sizeable negative operating and free cash flow, requiring continued funding to support trials. While cash burn improved versus 2024, persistent negative cash generation means financing risk and potential dilution remain structural until products generate operating cash flow.
Revenue Model Reliant On Collaborations And FinancingsDependence on upfronts, milestones, and partner-supported R&D creates revenue volatility and ties growth to third-party decisions. Without marketed products, durable revenue depends on successful partner programs and continued access to equity markets, which can be dilutive and uncertain over time.
Early-stage Pipeline And Execution RiskSeveral key programs are in Phase 1 or early development, exposing the company to high clinical attrition and long timelines. Even with promising data in select assets, structural development and approval risk across a multi-program pipeline means commercialization and durable revenue are not assured.
IDEAYA Biosciences News
IDYA FAQ
What was Ideaya Biosciences’s price range in the past 12 months?
Ideaya Biosciences lowest stock price was $22.09 and its highest was $40.58 in the past 12 months.
What is Ideaya Biosciences’s market cap?
Ideaya Biosciences’s market cap is $3.50B.
When is Ideaya Biosciences’s upcoming earnings report date?
Ideaya Biosciences’s upcoming earnings report date is Aug 11, 2026 which is in 13 days.
How were Ideaya Biosciences’s earnings last quarter?
Ideaya Biosciences released its earnings results on May 05, 2026. The company reported -$1.11 earnings per share for the quarter, missing the consensus estimate of -$0.989 by -$0.121.
Is Ideaya Biosciences overvalued?
According to Wall Street analysts Ideaya Biosciences’s price is currently Undervalued.
Does Ideaya Biosciences pay dividends?
Ideaya Biosciences does not currently pay dividends.
What is Ideaya Biosciences’s EPS estimate?
Ideaya Biosciences’s EPS estimate is -1.06.
How many shares outstanding does Ideaya Biosciences have?
Ideaya Biosciences has 95,083,145 shares outstanding.
What happened to Ideaya Biosciences’s price movement after its last earnings report?
Ideaya Biosciences reported an EPS of -$1.11 in its last earnings report, missing expectations of -$0.989. Following the earnings report the stock price went down -0.346%.
Which hedge fund is a major shareholder of Ideaya Biosciences?
Currently, no hedge funds are holding shares in IDYA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
IDEAYA Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.11 (52.86% Upside)
$54.11 (52.86% Upside)
Blogger Sentiment
Bullish
IDYA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 328.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.56%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-6.39%
Trailing 12-Months
Company Description
Ideaya Biosciences
IDEAYA Biosciences, Inc. (IDYA) is a clinical-stage precision oncology company in the biotechnology sector focused on discovering and developing targeted therapeutics and molecular diagnostics for genetically defined cancers. The company’s pipeline is built around synthetic lethality and other precision-medicine approaches, with drug candidates designed to treat patient populations selected by specific tumor biomarkers.
IDYA Stock 12 Month Forecast
Average Price Target
$54.11
▲(52.86% Upside)
Technical Analysis
Agios Pharma
―
Travere Therapeutics
―
Celcuity
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Ownership Overview
0.82% Insiders
27.92% Mutual Funds
0.64% Other Institutional Investors
55.30% Public Companies and
Individual Investors